Research and Clinical Trials

Brief Description  
The purpose of this study is to determine if patients with advanced transitional cell carcinoma treated with bevacizumab, gemcitabine and cisplatin will have increased overall survival when compared to patients treated with gemcitabine, cisplatin and placebo.
Who may be Eligible  
-Histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with progressive metastatic or locally advanced disease (T4b, N2, N3, or M1). Patients must not be candidates for potentially curative surgery or radiotherapy. -Patients may not have received combination systemic chemotherapy for metastatic disease. -No prior treatment with bevacizumab or other angiogenesis inhibitors. -ECOG performance status 0-1 (or KPS = 80) -Age = 18. -No known brain metastases.
IRB Number  
03-12-02A
Principal Investigator  
Mahoney, John

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Email:  Delois.DeShazo@carolinashealthcare.org
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203
Close